Current Status of Novel Multifunctional Targeted Pt(IV) Compounds and Their Reductive Release Properties
- PMID: 38398498
- PMCID: PMC10892972
- DOI: 10.3390/molecules29040746
Current Status of Novel Multifunctional Targeted Pt(IV) Compounds and Their Reductive Release Properties
Abstract
Platinum-based drugs are widely used in chemotherapy for various types of cancer and are considered crucial. Tetravalent platinum (Pt(IV)) compounds have gained significant attention and have been extensively researched among these drugs. Traditionally, Pt(IV) compounds are reduced to divalent platinum (Pt(II)) after entering cells, causing DNA lesions and exhibiting their anti-tumor effect. However, the available evidence indicates that some Pt(IV) derivatives may differ from the traditional mechanism and exert their anti-tumor effect through their overall structure. This review primarily focuses on the existing literature regarding targeted Pt(II) and Pt(IV) compounds, with a specific emphasis on their in vivo mode of action and the properties of reduction release in multifunctional Pt(IV) compounds. This review provides a comprehensive summary of the design and synthesis strategies employed for Pt(II) derivatives that selectively target various enzymes (glucose receptor, folate, telomerase, etc.) or substances (mitochondria, oleic acid, etc.). Furthermore, it thoroughly examines and summarizes the rational design, anti-tumor mechanism of action, and reductive release capacity of novel multifunctional Pt(IV) compounds, such as those targeting p53-MDM2, COX-2, lipid metabolism, dual drugs, and drug delivery systems. Finally, this review aims to provide theoretical support for the rational design and development of new targeted Pt(IV) compounds.
Keywords: anti-tumor; divalent platinum; multifunctional targeted; reductive release; tetravalent platinum.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures












Similar articles
-
Recent Approaches to Platinum(IV) Prodrugs: A Variety of Strategies for Enhanced Delivery and Efficacy.Curr Pharm Des. 2017;23(16):2366-2376. doi: 10.2174/1381612823666170201161037. Curr Pharm Des. 2017. PMID: 28155621 Review.
-
Effect of the aniline fragment in Pt(II) and Pt(IV) complexes as anti-proliferative agents. Standard reduction potential as a more reliable parameter for Pt(IV) compounds than peak reduction potential.J Inorg Biochem. 2021 May;218:111403. doi: 10.1016/j.jinorgbio.2021.111403. Epub 2021 Mar 9. J Inorg Biochem. 2021. PMID: 33730639
-
Supramolecular platinum complexes for cancer therapy.Curr Opin Chem Biol. 2023 Apr;73:102276. doi: 10.1016/j.cbpa.2023.102276. Epub 2023 Mar 4. Curr Opin Chem Biol. 2023. PMID: 36878171 Free PMC article. Review.
-
Nano-assembly of ursolic acid with platinum prodrug overcomes multiple deactivation pathways in platinum-resistant ovarian cancer.Biomater Sci. 2021 Jun 4;9(11):4110-4119. doi: 10.1039/d1bm00087j. Biomater Sci. 2021. PMID: 33949442
-
Vitamin B₁₂ as a carrier for targeted platinum delivery: in vitro cytotoxicity and mechanistic studies.J Biol Inorg Chem. 2011 Jan;16(1):33-44. doi: 10.1007/s00775-010-0697-z. Epub 2010 Aug 29. J Biol Inorg Chem. 2011. PMID: 20803225
Cited by
-
Pt(IV)-functionalised polyacrylic acid-coated iron oxide magnetic nanoparticles as redox-responsive cancer theranostics.J Mater Chem B. 2025 Jul 4. doi: 10.1039/d5tb01007a. Online ahead of print. J Mater Chem B. 2025. PMID: 40614086 Free PMC article.
-
Pt(IV) Complexes as Anticancer Drugs and Their Relationship with Oxidative Stress.Biomedicines. 2025 Apr 17;13(4):981. doi: 10.3390/biomedicines13040981. Biomedicines. 2025. PMID: 40299672 Free PMC article. Review.
-
Synthesis and anticancer activity of Pt(iv) prodrugs containing 3-bromopyruvic acid as an axial ligand.RSC Adv. 2025 Jun 30;15(27):22063-22075. doi: 10.1039/d5ra02064f. eCollection 2025 Jun 23. RSC Adv. 2025. PMID: 40589471 Free PMC article.
-
PEGylation Effects on Amphiphilic Platinum(IV) Complexes: Influence on Uptake, Activation, and Cytotoxicity.Pharmaceutics. 2025 Mar 29;17(4):440. doi: 10.3390/pharmaceutics17040440. Pharmaceutics. 2025. PMID: 40284435 Free PMC article.
-
Chemotherapeutic Potential of Chlorambucil-Platinum(IV) Prodrugs against Cisplatin-Resistant Colorectal Cancer Cells.Int J Mol Sci. 2024 Jul 28;25(15):8252. doi: 10.3390/ijms25158252. Int J Mol Sci. 2024. PMID: 39125821 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous